Bank of New York Mellon Corp Sells 41,846 Shares of Qiagen N.V. (NYSE:QGEN)

Bank of New York Mellon Corp lowered its position in shares of Qiagen N.V. (NYSE:QGEN) by 4.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 882,919 shares of the company’s stock after selling 41,846 shares during the quarter. Bank of New York Mellon Corp owned about 0.40% of Qiagen worth $35,449,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Brown Brothers Harriman & Co. bought a new stake in Qiagen during the fourth quarter valued at $37,000. EverSource Wealth Advisors LLC boosted its stake in Qiagen by 152.5% during the fourth quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company’s stock worth $39,000 after acquiring an additional 526 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in Qiagen by 770.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company’s stock worth $111,000 after acquiring an additional 2,204 shares in the last quarter. GAMMA Investing LLC boosted its stake in Qiagen by 93.9% during the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company’s stock worth $118,000 after acquiring an additional 1,425 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC bought a new position in Qiagen during the fourth quarter worth $202,000. Institutional investors own 70.00% of the company’s stock.

Analysts Set New Price Targets

QGEN has been the topic of several research analyst reports. Wall Street Zen raised shares of Qiagen from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 15th. Bank of America increased their target price on shares of Qiagen from $50.00 to $53.00 and gave the stock a “buy” rating in a research note on Thursday, June 26th. Barclays initiated coverage on shares of Qiagen in a research report on Tuesday, June 24th. They issued an “overweight” rating and a $55.00 price target for the company. Robert W. Baird lifted their price target on shares of Qiagen from $42.00 to $43.00 and gave the company a “neutral” rating in a research report on Monday, April 21st. Finally, Redburn Atlantic downgraded shares of Qiagen from a “buy” rating to a “neutral” rating in a research report on Friday, April 4th. Seven analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Qiagen presently has a consensus rating of “Hold” and an average price target of $49.40.

Qiagen Price Performance

Shares of NYSE QGEN opened at $48.25 on Tuesday. Qiagen N.V. has a twelve month low of $37.63 and a twelve month high of $49.30. The stock’s 50 day moving average price is $45.37 and its 200-day moving average price is $42.81. The company has a market capitalization of $10.73 billion, a PE ratio of 120.98, a PEG ratio of 2.45 and a beta of 0.68. The company has a quick ratio of 2.83, a current ratio of 3.37 and a debt-to-equity ratio of 0.40.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.50 by $0.05. Qiagen had a return on equity of 14.61% and a net margin of 4.68%. The business had revenue of $483.46 million for the quarter, compared to the consensus estimate of $465.66 million. During the same quarter in the prior year, the business earned $0.44 earnings per share. Qiagen’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, equities analysts anticipate that Qiagen N.V. will post 2.26 EPS for the current year.

Qiagen Dividend Announcement

The company also recently disclosed a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were issued a dividend of $0.25 per share. This represents a yield of 0.52%. The ex-dividend date was Wednesday, July 2nd. Qiagen’s dividend payout ratio (DPR) is 62.50%.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.